Sign In
Buy IOVA
$3.79
-0.310 (-7.56%)
At Close: Jun 03, 2026
Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma
05:15pm, Thursday, 05'th Feb 2026
52% Amtagvi Response Rate with Two or Fewer Prior Lines of Therapy 73% Overall Disease Control Rate 52% Amtagvi Response Rate with Two or Fewer Prior Lines of Therapy 73% Overall Disease Control Rate
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
05:15pm, Friday, 16'th Jan 2026
SAN CARLOS, Calif., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and deli
SAN DIEGO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) If you have held Iovance Biotherapeutics, Inc. shares continuously since prior to May 9, 2024, you may have st
2 Beaten-Down Stocks That Will Soar in 2026, According to Wall Street
09:30am, Monday, 29'th Dec 2025
A clinical hold and a complex commercial path make Intellia Therapeutics' outlook uncertain. Despite steadily growing revenue, Iovance Biotherapeutics faces nearly insurmountable challenges.
Iovance Biotherapeutics: Bright Prospects For 2026
12:51am, Monday, 29'th Dec 2025
Iovance Biotherapeutics is reaffirmed as a Buy, driven by Amtagvi's strong efficacy and blockbuster potential in melanoma and lung cancer. IOVA targets significant market expansion, with lung cancer r
Comparing Iovance Biotherapeutics (NASDAQ:IOVA) & Black Diamond Therapeutics (NASDAQ:BDTX)
03:17am, Thursday, 25'th Dec 2025
Black Diamond Therapeutics (NASDAQ: BDTX - Get Free Report) and Iovance Biotherapeutics (NASDAQ: IOVA - Get Free Report) are both small-cap medical companies, but which is the better business? We will
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
05:15pm, Friday, 19'th Dec 2025
SAN CARLOS, Calif., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and deli
2 Stocks That Could Soar by 52% and 282%, According to Wall Street
09:25am, Sunday, 07'th Dec 2025
CRISPR Therapeutics' approved medicine is making slow progress, but it has an exciting pipeline. Iovance Biotherapeutics is generating decent revenue, but it faces significant obstacles.
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
05:15pm, Friday, 21'st Nov 2025
SAN CARLOS, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and deli
AE Wealth Management LLC Makes New Investment in Iovance Biotherapeutics, Inc. $IOVA
03:02am, Wednesday, 19'th Nov 2025
AE Wealth Management LLC bought a new position in Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchan
Iovance Biotherapeutics: Base-Case Q3 Report Keeps 'Show Me' Mode
01:24pm, Tuesday, 11'th Nov 2025
Iovance Biotherapeutics remains a Sell due to ongoing dilution risk, sub-consensus revenue, and only modest margin improvements. Q3 revenue landed in the base case at $68 million, missing estimates, w
Down 75% in 12 Months, Can Iovance Biotherapeutics Stock Turn Things Around?
06:45am, Tuesday, 11'th Nov 2025
Iovance obtained approval for Amtagvi last year, which has given its top line a big boost. This year, the company anticipates it can generate up to $300 million in sales.
IOVA Soars 28% on Narrower-Than-Expected Loss in Q3, Revenues Up Y/Y
02:45pm, Friday, 07'th Nov 2025
Iovance's shares jump 28% as the biotech narrows its quarterly loss and lifts gross margins amid strong Amtagvi sales and cost cuts.
2 Small-Cap Stocks With Far More Upside Than Any "Magnificent Seven" Stock, According to Wall Street
08:45am, Friday, 07'th Nov 2025
Iovance Biotherapeutics and Intellia Therapeutics are two innovative small-cap biotechs. Both companies face serious issues despite Wall Street's high price targets for them.
Iovance Biotherapeutics, Inc. (IOVA) Q3 2025 Earnings Call Transcript
03:16pm, Thursday, 06'th Nov 2025
Iovance Biotherapeutics, Inc. ( IOVA ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Sara Pellegrino - Senior Vice President of Investor Relations & Corporate Communications
